Total | 1st trimester | 2nd trimester | 3rd trimester | P for trend | |||||
---|---|---|---|---|---|---|---|---|---|
n | (%) | n | (%) | n | (%) | n | (%) | ||
ICS or LABA | 0.678 | ||||||||
Neither ICS nor LABA | 2581 | (46.2) | 4084 | (73.1) | 3968 | (71) | 4060 | (72.6) | |
LABA only | 41 | (0.7) | 17 | (0.3) | 16 | (0.3) | 14 | (0.3) | |
ICS without LABA | 1407 | (25.2) | 633 | (11.3) | 730 | (13.1) | 663 | (11.9) | |
ICS with LABA | 1560 | (27.9) | 855 | (15.3) | 875 | (15.7) | 852 | (15.2) | |
ICS/LABA | |||||||||
Fluticasone/salmeterol | 1071 | (19.2) | 599 | (10.7) | 574 | (10.3) | 550 | (9.8) | 0.127 |
Budesonide/formoterol | 569 | (10.2) | 272 | (4.9%) | 319 | (5.7%) | 314 | (5.6%) | 0.079 |
ICS | |||||||||
Fluticasone | 74 | (1.3) | 30 | (0.5) | 39 | (0.7) | 41 | (0.7) | 0.198 |
Budesonide | 1236 | (22.1) | 550 | (9.8) | 626 | (11.2) | 574 | (10.3) | 0.458 |
Other ICS | 115 | (2.1) | 57 | (1) | 67 | (1.2) | 55 | (1) | 0.854 |
LABA | |||||||||
Salmeterol | 40 | (0.7) | 17 | (0.3) | 16 | (0.3) | 13 | (0.2) | 0.470 |
Formoterol | 1 | (0.0) | 0 | (0.0) | 0 | (0.0) | 1 | (0.0) | 0.221 |
SABA | 1805 | (32.3) | 901 | (16.1) | 924 | (16.5) | 772 | (13.8) | 0.001 |
LTRA | 1620 | (29) | 1081 | (19.3) | 675 | (12.1) | 516 | (9.2) | <0.001 |
Theophylline | 515 | (9.2) | 283 | (5.1) | 159 | (2.8) | 105 | (1.9) | <0.001 |
Systemic steroids | 509 | (9.1) | 301 | (5.4) | 214 | (3.8) | 201 | (3.6) | <0.001 |
ICS, inhaled corticosteroids; LABA, long-acting β2-agonists; LTRA, leukotriene receptor antagonists; SABA, short-acting β2-agonists.